Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report

Clinical trials of chimeric antigen receptors (CARs) targeting CD19 have produced impressive results in hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). However, a notable number of patients with DLBCL fail to achieve remission after CD19 CAR T-cell therapy and may theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chen, Zhang, Hui-Chao, Ho, Jin-Yuan, Liu, Rui-Xia, Wang, Lin, Kuang, Na, Zheng, Mei-Rong, Liu, Li-Hong, Li, Jian-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405542/
https://www.ncbi.nlm.nih.gov/pubmed/32774494
http://dx.doi.org/10.3892/ol.2020.11882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405542/
https://www.ncbi.nlm.nih.gov/pubmed/32774494
http://dx.doi.org/10.3892/ol.2020.11882

Ejemplares similares